User:Mr. Ibrahem/Ibrutinib

Ibrutinib, sold under the brand name Imbruvica among others, is a medication used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia. It is used in MCL and CLL when other treatments have failed. Other uses may include graft versus host disease. It is taken by mouth.

Common side effects include low platelets, low red blood cells, low white blood cells, diarrhea, rash, bleeding, and mouth inflammation. Other side effects may include infection, heart failure, high blood pressure, other cancers, and tumor lysis syndrome. Use in pregnancy may harm the baby. It works by blocking Bruton's tyrosine kinase (BTK) which slows B cell division.

Ibrutinib was approved for medical use in the United States in 2013 and Europe in 2014. It is on the World Health Organization's List of Essential Medicines as a complementary item. Generic versions have been approved. In the United Kingdom 4 weeks of treatment costs the NHS about £5,000 as of 2021. This amount in the United States costs about 14,500 USD.